OR WAIT 15 SECS
The acquisition comes after Bormioli became an independent company owned by Triton Investment Fund in December 2017.
Bormioli Pharma, a pharmaceutical and biopharmaceutical plastic containers, closures, and packaging accessories company headquartered in Italy, announced it completed its acquisition of Remy & Geiser (R&G), a German plastic and glass product company.
According to an Oct. 8, 2019 press release, the acquisition comes after Bormioli became an independent company owned by Triton Investment Fund in December 2017.
“This acquisition is part of a wider development plan aimed to make of Bormioli Pharma a truly global and innovative player,” said Andrea Lodetti, CEO, Bormioli, in the press release. “Through this operation Bormioli Pharma reinforces its presence in the German and Northern European markets, expands its current offering with complementary products and strengthens its manufacturing footprint adding more technological capabilities.”
R&G develops, manufactures, and closes sales for dosing systems, pipette droppers, and tubular glass vials, according to the release. The company has about 270 employees and two plants located in Germany.
“We are proud to become a part of a solid and international group like Bormioli Pharma,” added Dr. Friedrich Hillebrand, R&G’s owner, in the press release. “With this step Remy & Geiser achieves further development potential and broadens its future horizons. It is a project I strongly believe in, and I am honored to join the Group as [m]ember of the [b]oard of [d]irectors.”
Bormioli will be at Booth 111C10 and R&G will be at Booth 111C51 at CPhI Worldwide on Nov. 5–7 in Frankfurt, Germany.
Source: Bormioli Pharma